(Circulation. 2000;102:2353.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Oral Magnesium Therapy Improves Endothelial Function in Patients With Coronary Artery Disease
From the Preventive & Rehabilitative Cardiac Center and the Atherosclerosis Research Center, Cedars-Sinai Burns and Allen Research Institute, the Division of Cardiology, Department of Medicine, Cedars-Sinai Medical Center, and the University of California Los Angeles School of Medicine (M. Shechter, M. Sharir, M.J.P.L., J.F., C.N.B.M.); and IntraCellular Diagnostics, Inc (B.S.), Foster City, Calif.
Correspondence to Michael Shechter, MD, MA, FACC, Preventive & Rehabilitative Cardiac Center, Cedars-Sinai Medical Center, 444 San Vicente Blvd, Suite 901, Los Angeles, CA 90048. E-mail shechtes{at}netvision.net.il
Background—Magnesium blocks many of the physiological actions of calcium. Nevertheless, the impact of magnesium supplementation on endothelial function and exercise tolerance in stable coronary artery disease (CAD) patients has not been assessed.
Methods and Results—In a randomized, double-blind, placebo-controlled trial, 50 stable CAD patients (41 men and 9 women, mean±SD age 67±11 years, age range 42 to 82 years) were randomized to receive either magnesium (n=25) (30 mmol/d Magnosolv-Granulat; Asta Medica Company, Inc) or placebo (n=25) for 6 months. Before and after 6 months, endothelium-dependent brachial artery flow-mediated vasodilation (FMD) and endothelium-independent NTG-mediated vasodilation were assessed with high-resolution (10-MHz) ultrasound. Exercise stress testing was performed with use of the Bruce protocol. Intracellular magnesium concentrations ([Mg2+]i) were assessed from sublingual cells through x-ray dispersion (EXA) (normal mean±SD values 37.9±4.0 mEq/L). The magnesium therapy significantly increased postintervention ([Mg2+]i versus placebo (36.2±5.0 versus 32.7±2.7 mEq/L, P<0.02). There was a significant correlation in the total population between baseline [Mg2+]i and baseline FMD (r=0.48, P<0.01). The magnesium intervention resulted in a significant improvement in postintervention FMD (15.5±12.0%, P=0.02 compared with baseline), which was not evident with placebo (4.4±2.5%, P=0.78 compared with baseline). There was better exercise tolerance (9.3±2.0 versus 7.3±3.1 minutes, P=0.05) and less ischemic ST-segment changes (4 versus 10 patients, P=0.05) in the magnesium versus placebo groups, respectively.
Conclusions—Oral magnesium therapy in CAD patients is associated with significant improvement in brachial artery endothelial function and exercise tolerance, suggesting a potential mechanism by which magnesium could beneficially alter outcomes in CAD patients.
Key Words: magnesium • lipoproteins • endothelium • coronary disease
This article has been cited by other articles:
 |
|
 |
|
  T. Lavi, A. Karasik, N. Koren-Morag, H. Kanety, M. S. Feinberg, and M. Shechter The acute effect of various glycemic index dietary carbohydrates on endothelial function in nondiabetic overweight and obese subjects. J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2283 - 2287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shechter, S. Matetzky, M. Arad, M. S. Feinberg, and D. Freimark Vascular endothelial function predicts mortality risk in patients with advanced ischaemic chronic heart failure Eur J Heart Fail, June 1, 2009; 11(6): 588 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ros Nuts and novel biomarkers of cardiovascular disease Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1649S - 1656S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. I. Khalpey, R. B. Ganim, and J. D. Rawn Postoperative Care of Cardiac Surgery Patients Card. Surg. Adult, January 1, 2008; 3(2008): 465 - 486. [Full Text]
|
|
|
|
|
|
Y. Song, T. Y Li, R. M van Dam, J. E Manson, and F. B Hu Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women Am. J. Clinical Nutrition, April 1, 2007; 85(4): 1068 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bo, M. Durazzo, S. Guidi, M. Carello, C. Sacerdote, B. Silli, R. Rosato, M. Cassader, L. Gentile, and G. Pagano Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. Am. J. Clinical Nutrition, November 1, 2006; 84(5): 1062 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Pokan, P Hofmann, S P von Duvillard, G Smekal, M Wonisch, K Lettner, P Schmid, M Shechter, B Silver, and N Bachl Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients Br. J. Sports Med., September 1, 2006; 40(9): 773 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Paul-Labrador, D. Polk, J. H. Dwyer, I. Velasquez, S. Nidich, M. Rainforth, R. Schneider, and C. N. B. Merz Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease. Arch Intern Med, June 12, 2006; 166(11): 1218 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. de Araujo, L. Andrade, T. M. Coimbra, A. C. Rodrigues Jr, and A. C. Seguro Magnesium Supplementation Combined with N-Acetylcysteine Protects against Postischemic Acute Renal Failure J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3339 - 3349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tsuji, K. Araki, K. Maeyama, and K. Hashimoto Effectiveness of Oral Magnesium in a Patient With Ventricular Tachycardia Due to Hypomagnesemia Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2005; 10(3): 205 - 208. [Abstract] [PDF]
|
|
|
|
 |
|
 A. L. Moens, I. Goovaerts, M. J. Claeys, and C. J. Vrints Flow-Mediated Vasodilation: A Diagnostic Instrument, or an Experimental Tool? Chest, June 1, 2005; 127(6): 2254 - 2263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Bots, J. Westerink, T. J. Rabelink, and E. J.P. de Koning Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response Eur. Heart J., February 2, 2005; 26(4): 363 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Silver Development of Cellular Magnesium Nano-Analysis in Treatment of Clinical Magnesium Deficiency J. Am. Coll. Nutr., December 1, 2004; 23(6): 732S - 737S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shechter, E. Ros, I. Nunez, A. Perez-Heras, M. Serra, R. Gilabert, E. Casals, and R. Deulofeu Walnuts and Endothelial Function in Hypercholesterolemic Subjects * Response Circulation, August 3, 2004; 110(5): e58 - e58. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Amighi, S. Sabeti, O. Schlager, W. Mlekusch, M. Exner, W. Lalouschek, R. Ahmadi, E. Minar, and M. Schillinger Low Serum Magnesium Predicts Neurological Events in Patients With Advanced Atherosclerosis Stroke, January 1, 2004; 35(1): 22 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shechter, S. Matetzky, M. S. Feinberg, P. Chouraqui, Z. Rotstein, and H. Hod External counterpulsation therapy improves endothelial function in patients with refractory angina pectoris J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2090 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Ford and A. H. Mokdad Dietary Magnesium Intake in a National Sample of U.S. Adults J. Nutr., September 1, 2003; 133(9): 2879 - 2882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Davies and A. Struthers Review: The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus Journal of Renin-Angiotensin-Aldosterone System, September 1, 2002; 3(3): 150 - 155. [Abstract] [PDF]
|
|
|
|
 |
|
 S. A. Bell, D. Strassberg, and M. L. Knudtson Chelation Therapy for Patients With Ischemic Heart Disease JAMA, April 24, 2002; 287(16): 2077 - 2078. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kelm Flow-mediated dilatation in human circulation: diagnostic and therapeutic aspects Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H1 - H5. [Full Text] [PDF]
|
|